Mauritania - Prevalence of HIV, total (% of population ages 15-49)

Prevalence of HIV, total (% of population ages 15-49) in Mauritania was 0.200 as of 2018. Its highest value over the past 28 years was 0.500 in 2006, while its lowest value was 0.100 in 1990.

Definition: Prevalence of HIV refers to the percentage of people ages 15-49 who are infected with HIV.

Source: UNAIDS estimates.

See also:

Year Value
1990 0.100
1991 0.100
1992 0.100
1993 0.100
1994 0.200
1995 0.200
1996 0.300
1997 0.300
1998 0.400
1999 0.400
2000 0.400
2001 0.500
2002 0.500
2003 0.500
2004 0.500
2005 0.500
2006 0.500
2007 0.400
2008 0.400
2009 0.400
2010 0.400
2011 0.400
2012 0.300
2013 0.300
2014 0.300
2015 0.300
2016 0.200
2017 0.200
2018 0.200

Limitations and Exceptions: The limited availability of data on health status is a major constraint in assessing the health situation in developing countries. Surveillance data are lacking for many major public health concerns. Estimates of prevalence and incidence are available for some diseases but are often unreliable and incomplete. National health authorities differ widely in capacity and willingness to collect or report information.

Statistical Concept and Methodology: HIV prevalence rates reflect the rate of HIV infection in each country's population. Low national prevalence rates can be misleading, however. They often disguise epidemics that are initially concentrated in certain localities or population groups and threaten to spill over into the wider population. In many developing countries most new infections occur in young adults, with young women especially vulnerable. Data on HIV are from the Joint United Nations Programme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions for estimating the data and better coordination with countries have resulted in improved estimates of HIV and AIDS. The models, which are routinely updated, track the course of HIV epidemics and their impact, making full use of information in HIV prevalence trends from surveillance data as well as survey data. The models take into account reduced infectivity among people receiving antiretroviral therapy (which is having a larger impact on HIV prevalence and allowing HIV-positive people to live longer) and allow for changes in urbanization over time in generalized epidemics. The estimates include plausibility bounds, which reflect the certainty associated with each of the estimates.

Aggregation method: Weighted average

Periodicity: Annual

Classification

Topic: Health Indicators

Sub-Topic: Risk factors